Skip to content
StackItSmart
BHuman cohort / observational
Hypoglycemia risk

Berberine

Berberine is a plant-derived isoquinoline alkaloid (from Coptis, Berberis/goldenseal, Hydrastis) marketed as an ancillary "organ-support" / metabolic supplement. Human RCTs and their meta-analyses show modest reductions in fasting and post-prandial glucose, HbA1c, LDL/total cholesterol and triglycerides, which is why it is used adjunctively for dyslipidemia, insulin resistance, NAFLD and PCOS. The main risks are not dramatic organ toxicity but (1) frequent GI intolerance (diarrhea, constipation, cramping); (2) clinically important drug interactions: berberine inhibits CYP3A4 and P-glycoprotein and can raise blood levels of narrow-therapeutic-index drugs (e.g., cyclosporine); (3) displacement of bilirubin from albumin, making it hazardous in pregnancy and in neonates (kernicterus risk); and (4) additive hypoglycemia when combined with antidiabetic drugs. Most trials are small, short (typically 8-24 weeks), of low-to-moderate methodological quality, and long-term safety is not established. This is not a performance or physique agent and should be treated as a pharmacologically active substance, not a benign supplement.

Clinical readoutAncillary · organ-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
Reported human pl…
Route
Oral
Evidence
B
Active
Dosed 2-3 times daily i…
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Reported human plasma elimination is prolonged and variable; terminal half-life estimates commonly span several hours to ~10-24+ hours owing to tissue distribution and slow release, but data are inconsistent because of extensive metabolism and very low plasma concentrations. Active metabolites circulate longer than parent drug.
Pharmacology

Mechanism of action

Berberine is pleiotropic. The best-supported metabolic mechanism is activation of AMP-activated protein kinase (AMPK), which reduces hepatic gluconeogenesis and lipogenesis and improves peripheral insulin sensitivity. It upregulates hepatic LDL-receptor expression (post-transcriptional stabilization of LDLR mRNA, distinct from statins) to lower LDL cholesterol, and inhibits PCSK9. Additional actions include inhibition of intestinal DPP-4, modulation of the gut microbiota (shifting Firmicutes/Bacteroidetes ratio and short-chain fatty acid production), and anti-inflammatory effects. Because oral bioavailability is very low, much of its in-vivo effect is attributed to gut-level action and to active metabolites (berberrubine, demethyleneberberine, columbamine, jatrorrhizine). It is also an inhibitor of CYP3A4 and intestinal P-glycoprotein, which underlies its interaction potential.
Kinetics

Pharmacokinetics

Half-life

Reported human plasma elimination is prolonged and variable; terminal half-life estimates commonly span several hours to ~10-24+ hours owing to tissue distribution and slow release, but data are inconsistent because of extensive metabolism and very low plasma concentrations. Active metabolites circulate longer than parent drug.

Active duration

Dosed 2-3 times daily in trials, consistent with a functional duration of roughly 8-12 hours per dose for metabolic effects.

Route

Oral (essentially the only route used clinically).

Metabolism & clearance

Very low oral bioavailability (<1%) due to poor absorption, intestinal P-gp efflux, and extensive first-pass metabolism. Undergoes phase I metabolism (demethylation, demethylenation, reduction, hydroxylation) and phase II conjugation, primarily hepatic, yielding pharmacologically active metabolites. Excreted via bile/feces and urine. This information is for washout/monitoring context only.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Lowers fasting plasma glucose, 2-hour postprandial glucose and HbA1c in type 2 diabetes (meta-analysis of RCTs)
  • Improves insulin resistance (lower fasting insulin and HOMA-IR)
  • Reduces total cholesterol, LDL cholesterol and triglycerides and modestly raises HDL
  • Modest reductions in body weight/BMI in metabolic populations
  • Adjunctive improvement of endocrine/metabolic parameters in PCOS (insulin resistance), though inferior to metformin/inositol combinations for some outcomes
  • Improvement in NAFLD-related biochemical and imaging parameters when combined with lifestyle change (limited-quality evidence)
  • Lowers inflammatory markers (CRP, IL-6, TNF-alpha) in some trials
Safety

Adverse effects by system

Cardiovascular

No signal of direct cardiotoxicity in oral human metabolic trials; QT prolongation/arrhythmia has not been specifically studied for berberine and no adequate human arrhythmia data exist, so this theoretical risk cannot be excluded. Blood-pressure and heart-failure benefits are preclinical/mechanistic only.

Hepatic

Generally regarded as hepatoprotective in metabolic disease (used for NAFLD); no consistent signal of drug-induced liver injury in trials. However, as a CYP3A4 inhibitor it can raise hepatically-metabolized drug levels, and rigorous long-term hepatic safety data are lacking.

Endocrine / HPTA

Not an androgen, SERM, or aromatase-active agent; no direct effect on the male hypothalamic-pituitary-gonadal axis is established. It lowers glucose/insulin and improves insulin resistance, and in PCOS it modestly affects androgen-related metabolic parameters; additive hypoglycemia with antidiabetic drugs is the main endocrine hazard.

Reproductive

Contraindicated in pregnancy: berberine displaces bilirubin from albumin (preclinical/in-vitro and rat data) and traditional huanglian use is linked to kernicterus risk in jaundiced neonates. Effects on human fertility are not adequately studied.

Neuropsychiatric

No established psychiatric adverse effects in humans; no adequate data.

Renal

No clear nephrotoxic signal; trials monitoring serum creatinine and BUN did not show harm. Dedicated renal-safety data are limited.

Hematologic

Main documented hematologic hazard is displacement of protein-bound bilirubin, raising free bilirubin (kernicterus risk in neonates); it can also displace or interact with other highly protein-bound drugs. No consistent effect on blood counts reported, but data are limited.

Dermatologic

No characteristic dermatologic toxicity reported; occasional rash is possible but not well documented.

Recovery

HPTA suppression & recovery

Suppression: None expected — berberine is not a hormonal/SERM/androgenic agent and has no established mechanism of hypothalamic-pituitary-gonadal suppression.

No HPTA suppression is described in the literature, so no recovery protocol applies. Berberine is single-agent, non-hormonal; dual-SERM or SERM protocols are not relevant here. Any concern about hormonal or fertility effects, or use alongside hormonal therapy, should be directed to an endocrinologist rather than self-managed.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Fasting glucose and HbA1c (especially if combined with any antidiabetic therapy)Lipid panelLiver function tests (ALT, AST, bilirubin)Renal function (creatinine, BUN)Blood levels of any co-administered narrow-therapeutic-index drug (e.g., cyclosporine, tacrolimus, digoxin) via the prescribing clinician

Cadence: Baseline before starting, then at roughly 8-12 weeks; more frequently (including drug-level checks) when co-administered with interacting or glucose-lowering medications, and any time symptoms develop.

Warning signs — seek care
  • Symptoms of hypoglycemia (shakiness, sweating, confusion, palpitations)
  • Persistent or severe diarrhea, constipation, or abdominal cramping
  • Jaundice, dark urine, or right-upper-quadrant pain
  • Signs of toxicity from a co-administered drug (e.g., digoxin or cyclosporine toxicity)
  • New rash or allergic symptoms
Do not use if

Contraindications

  • Pregnancy and breastfeeding (bilirubin displacement; kernicterus risk)
  • Neonates and jaundiced infants — avoid berberine-containing herbs entirely
  • Concurrent narrow-therapeutic-index CYP3A4 or P-gp substrates without physician supervision (e.g., cyclosporine, tacrolimus, digoxin, certain tyrosine-kinase inhibitors)
  • Concurrent insulin or insulin-secretagogues/other glucose-lowering drugs without medical monitoring (additive hypoglycemia)
  • Known hypersensitivity to berberine or source botanicals
  • Significant hepatic or renal impairment without clinician oversight (limited safety data)
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Treat berberine as a drug with real interactions, not a harmless supplement; disclose it to every prescriber and pharmacist.
  • Do not combine with insulin or other glucose-lowering drugs without medical supervision and glucose monitoring — additive hypoglycemia can occur.
  • Avoid entirely in pregnancy, breastfeeding, and in/around neonates because of bilirubin-displacement and kernicterus risk.
  • Avoid or use only under physician supervision with narrow-therapeutic-index CYP3A4/P-gp substrates (cyclosporine, tacrolimus, digoxin, some tyrosine-kinase inhibitors); drug-level monitoring is essential.
  • GI upset (diarrhea, constipation, cramping) is the most common reason to stop; persistent or severe GI symptoms warrant discontinuation.
  • Stop and seek care promptly for jaundice, dark urine, hypoglycemic episodes, or signs of toxicity from a co-administered medication.
  • Get baseline and follow-up bloodwork (glucose/HbA1c, lipids, LFTs, renal function) and work with a clinician rather than self-titrating; long-term safety is not established.
Evidence

Citations (14)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Berberine reduces HbA1c, fasting and postprandial glucose, fasting insulin and HOMA-IR, and improves lipids in type 2 diabetes (RCT meta-analysis).

    Meta-analysisPMID 34956436 ↗

  2. 02

    Umbrella review of RCT meta-analyses: berberine affects glucose, insulin resistance, lipids, body composition and inflammatory markers; common side effects are GI (constipation, diarrhea); evidence is often of low methodological quality.

    Meta-analysisPMID 36999891 ↗

  3. 03

    Berberine-containing nutraceutical combinations significantly lower total and LDL cholesterol, triglycerides and glucose and modestly raise HDL.

    Meta-analysisPMID 27157250 ↗

  4. 04

    Berberine plus silymarin improves total cholesterol, LDL, triglycerides, HDL and fasting plasma glucose.

    Meta-analysisPMID 30632209 ↗

  5. 05

    Berberine improves endocrine/metabolic parameters in PCOS but is generally less effective than metformin- or inositol-based comparators for several outcomes.

    Meta-analysisPMID 34407851 ↗

  6. 06

    Berberine has very low oral bioavailability with extensive first-pass metabolism (demethylation, demethylenation, reduction, hydroxylation, conjugation) and pharmacologically active metabolites.

    ReviewPMID 28290706 ↗

  7. 07

    Berberine's poor systemic bioavailability and gut-microbiota modulation underlie much of its metabolic pharmacology.

    ReviewPMID 32105754 ↗

  8. 08

    Clinical evidence supports berberine use in type 2 diabetes, obesity, NAFLD, hyperlipidemia and gout, but larger, longer, multicenter trials are needed to confirm efficacy and safety.

    ReviewPMID 33186794 ↗

  9. 09

    In healthy volunteers, berberine increased the oral bioavailability (AUC, C12) of cyclosporine A, attributed to CYP3A4 and gut-level inhibition.

    RCTPMID 16541194 ↗

  10. 10

    Berberine increases bioavailability of P-gp/CYP3A substrates (digoxin, cyclosporine) via intestinal P-glycoprotein inhibition (preclinical).

    PreclinicalPMID 19370549 ↗

  11. 11

    PBPK modeling predicts high-dose berberine and goldenseal can raise exposure of CYP3A/P-gp substrates (e.g., bosutinib), warranting caution with co-administration.

    PreclinicalPMID 35048143 ↗

  12. 12

    Berberine displaces bilirubin from albumin (about tenfold more potent than phenylbutazone in vitro) and raises unbound/total bilirubin in rats; use is best avoided in jaundiced neonates and pregnant women (kernicterus risk).

    PreclinicalPMID 8513024 ↗

  13. 13

    Berberine is among nutraceuticals with clinical evidence for improving NAFLD-related parameters when combined with lifestyle change.

    ReviewPMID 30142943 ↗

  14. 14

    Cardiac/heart-failure mechanisms of berberine remain preclinical and network-pharmacology based; clinical cardiac efficacy and safety are unproven.

    PreclinicalPMID 40833320 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice